Denise Grippo
About Denise Grippo
Denise Grippo serves as Vice President at Geron Corporation, where she has worked since 2019. With extensive experience in quality management and compliance, she has held key positions at various biotechnology firms, including Iovance Biotherapeutics and XenoPort.
Work at Geron Corporation
Denise Grippo has served as Vice President at Geron Corporation since 2019. Located in Menlo Park, California, she has been instrumental in overseeing quality management and compliance systems within the organization. Her role involves ensuring that the company's operations align with regulatory standards and industry best practices.
Previous Experience in Biopharmaceuticals
Prior to her current position, Denise Grippo held several key roles in the biopharmaceutical sector. She worked as Executive Director of GMP Quality at XenoPort, Inc. from 2015 to 2016. Following this, she served as Vice President of Quality at Iovance Biotherapeutics, Inc. from 2016 to 2019, where she focused on quality assurance processes.
Education and Expertise
Denise Grippo earned her Master of Science in Clinical Chemistry from the University of Scranton, studying from 1998 to 2000. She also holds a Bachelor of Science in Biology from Temple University, completed between 1994 and 1998. Her educational background supports her expertise in developing Quality and Compliance systems for various organizations.
Specialization in Quality Management Systems
Denise Grippo specializes in implementing and harmonizing Global Quality Management Systems. Her skills include internal and external auditing, contract and quality agreements, and employee relations. She has extensive experience in both early-stage start-ups and established companies, contributing to the development of robust quality frameworks.
Career Development and Consulting
Before her roles in biopharmaceutical companies, Denise Grippo worked as a Senior Consultant at Validant in 2012 for five months. She also served as Senior Director of Global Quality Assurance at Mylan from 2012 to 2015, where she played a key role in enhancing global quality assurance practices.